
Sandip Patel/stemcells.ucsd.edu
Jun 28, 2025, 16:44
Sandip Patel Highlights the Role of Full Genomic Profiling in Stage IV NSCLC – DAVA Oncology
DAVA Oncology shared a post on X:
“Dr. Sandip Patel at DAVA Lung highlights the role of full genomic profiling in Stage IV NSCLC. For EGFR mutations: osimertinib, chemo-osimertinib, or amivantamab+lazertinib. Future strategies may hinge on molecular risk and balancing patient burden.”
More posts featuring DAVA Oncology.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 28, 2025, 16:22
Jun 28, 2025, 16:07
Jun 28, 2025, 15:34
Jun 28, 2025, 15:15
Jun 28, 2025, 15:15